Pfizer and Bristol-Myers Squibb Co. announced that apixaban, an anti-clotting treatment, failed to outperform Sanofi-Aventis' Lovenox in warding off venous thromboembolisms in knee-replacement patients during a Phase III trial. The companies are postponing plans to seek FDA approval for such use, but they are considering further studies in this avenue.

Related Summaries